Gemtesa 75 mg (Vibegron Tablet) 75mg

Vibegron, the active ingredient in Gemtesa, works by selectively targeting beta-3 adrenergic receptors. This action relaxes the detrusor smooth muscle of the bladder, increasing bladder capacity and reducing symptoms of urgency and frequency associated with overactive bladder.

The usual dose of Gemtesa is one 75 mg tablet taken by mouth once daily. The prescriber will determine the appropriate dosage based on individual patient needs and medical history.

It is not known if Gemtesa will harm an unborn baby or if it passes into breast milk. Patients who are pregnant, planning to become pregnant, or breastfeeding should consult their doctor before taking Gemtesa.

To order Gemtesa from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

Gemtesa is a selective beta-3 adrenergic receptor agonist, which differs from other overactive bladder medications that may act on different receptors or pathways. The choice of medication depends on individual patient needs, medical history, and the prescriber's recommendation.

Gemtesa should be stored at room temperature, between 68°F to 77°F (20°C to 25°C). Short-term exposure to 59°F to 86°F (15°C to 30°C) is acceptable. Keep the medication out of reach of children and in its original packaging to protect from moisture.

Gemtesa is administered orally as a 75 mg tablet, taken once daily. The tablet should be swallowed whole with water, and it can be taken with or without food. The prescriber will provide specific instructions based on the patient's needs.

The most serious risks associated with Gemtesa include angioedema, which is characterized by swelling of the lips, face, tongue, or throat, with or without difficulty breathing. Another serious risk is urinary retention, especially in patients with bladder outlet obstruction. Patients should seek immediate medical attention if they experience these symptoms.

Patients who are allergic to vibegron or any of the ingredients in Gemtesa should not take this medication. Additionally, patients with severe liver or kidney problems, or those who have difficulty emptying their bladder, should consult their doctor before taking Gemtesa.